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Objective. To improve PMTCT and antenatal care-related service delivery, a pack with centrally prepackaged medicine was rolled
out to all pregnant women in Lesotho in 2011. This study assessed acceptability and feasibility of this copackaging mechanism for
drug delivery among pregnant and postpartum women. Methods. Acceptability and feasibility were assessed in a mixed method,
cross-sectional study through structured interviews (SI) and semistructured interviews (SSI) conducted in 2012 and 2013. Results.
290 HIV-negative women and 437 HIV-positive women (𝑛 = 727) participated. Nearly all SI participants found prepackaged
medicines acceptable, though modifications such as size reduction of the pack were suggested. Positive experiences included that the
pack helped women take pills as instructed and contents promoted healthy pregnancies. Negative experiences included inadvertent
pregnancy disclosure and discomfort carrying the pack in communities. Implementation was also feasible; 85.2% of SI participants
reported adequate counseling time, though 37.8% felt pack use caused clinic delays. SSI participants reported improvement in
service quality following pack introduction, due to more comprehensive counseling. Conclusions. A prepackaged drug delivery
mechanism for ANC/PMTCT medicines was acceptable and feasible. Findings support continued use of this approach in Lesotho
with improved design modifications to reflect the current PMTCT program of lifelong treatment for all HIV-positive pregnant
women.

1. Introduction
In 2013, 240,000 children were newly infected with HIV, a
58% decline in new pediatric infections since 2002 [1]. There
is demonstrated ability to reduce rates of new pediatric HIV
infections to less than 5% in Africa, but access to programs for
HIV prevention of mother-to-child transmission (PMTCT),
uptake, and adherence to drugs are required [2–6].
Literature is replete with documentation of barriers that
limit the efficient scale-up and performance of national

PMTCT programs. Weak commodity procurement and distribution mechanisms, limited laboratory infrastructure,
poor integration of services, limited human resources, and
lack of community or patient-centeredness are barriers that
limit the health sector’s ability to provide the needed services
[7]. Challenges with drug stock-outs and monthly dispensing
of antenatal Zidovudine (AZT) caused women to make several visits to antenatal care (ANC), potentially deterring them
from returning, and thus decreasing PMTCT drug adherence
and program effectiveness [8]. A variety of social, behavioral,
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and structural barriers operate beyond the influence of the
health facility, limiting HIV/AIDS services demand from
target individuals and communities [9]. Barriers include
late ANC presentation, preventing the early initiation of
antiretroviral (ARV) drugs for either treatment or prophylaxis, transport costs for women in rural areas, poor retention
in services, perceived poor quality of services, lack of support
from husbands, lack of privacy, and negative or judgmental
attitudes of health workers towards HIV-infected women
[8, 10, 11].
In Lesotho, 22.9% are living with HIV and HIV prevalence among pregnant women attending ANC is higher than
the national average at 25.9% [1, 12]. Ninety-five percent
of pregnant women attend at least one ANC visit. While
healthcare engagement is improving, one-quarter of women
do not attend the World Health Organization- (WHO-)
recommended minimum of four ANC visits nor do they
deliver in a facility [13]. As Lesotho is mountainous and the
majority of the population lives in rural areas, long distances
to clinics, weather conditions, and rough terrain negatively
impact the accessibility of critical ANC and PMTCT services.
To address some of the operational challenges and decrease
MTCT risk for HIV-positive women with limited interactions
with the healthcare system, the mother/baby copackage
was developed to deliver ARV medications to HIV-positive
pregnant women aligned with the WHO guidelines at the
time (Option A in 2010) [14].
The mother/baby copackage was adapted from the Minimum PMTCT Package (MPP), implemented in 2007 by the
Ministry of Health (MOH) in Lesotho. The MPP contained
facility prepackaged drugs in plain envelopes distributed at
the first ANC visit for HIV-positive pregnant women and
their infants. While both the MPP and copackage were based
on a similar drug prepackaging concept, the MPP differed in
significant ways including the packaging, contents, and context in which it was provided. The MPP was found to be feasible and acceptable to providers and clients, though challenges
such as stock-outs and provision of adequate instruction on
the use of multiple medications were noted [15].
The copackage is a color-coded rectangular box, measuring 255 mm × 182 mm × 130 mm (Figure 1). Each pack
contained smaller packages inside representing the antenatal,
intrapartum, and postpartum periods of pregnancy. The
outer bag was also rectangle-shaped and made of dark blue
cloth with no words or other markings. To minimize potential
stigmatization associated with the pack, three package types
were implemented: Pack 1 for HIV-negative women, Pack
2 for HIV-positive women eligible for PMTCT prophylaxis,
and Pack 3 for HIV-positive women on antiretroviral treatment (ART). (All packs contained iron, folic acid, Vitamin
A, and Vitamin B-complex. In addition, Pack 2 contained
AZT tablets from 14 weeks of gestation to delivery and
AZT/3TC (fixed dose combination) and Nevirapine tablets
for delivery and 7 days postpartum. Providers administering
the pack removed excess AZT from the pack based on the
gestational age at which the woman received the pack. Pack 2
and Pack 3 also contained Nevirapine syrup with a syringe
for administration to the infant until 6 weeks of age.) The
packs were assembled and filled centrally and distributed
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Figure 1: The pack and its inner boxes and instruction sheet. Counterclockwise from the left. (1) Outer pack identical for all women
(size: 255 mm × 182 mm × 130 mm). (2) Instruction sheet written in
Sesotho. (3) Blue inner box containing medicine to be taken during
pregnancy: (i) ferrous sulphate, folic acid, and Vitamin B-complex
for all women; (ii) Zidovudine (AZT) for HIV-positive women on
ARV prophylaxis. (4) Yellow inner box containing medicine to be
taken during delivery: (i) AZT/Lamivudine (3TC) in fixed dose
combination and Nevirapine tablets for HIV-positive women on
ARV prophylaxis. (5) Pink inner box containing medicine for the
mother to be taken postpartum: (i) AZT/3TC 7-day “tail” in fixed
dose combination for HIV-positive women on ARV prophylaxis; (ii)
vitamin A for all women. (6) Pink inner box containing medicine
for the infant through six weeks of age: (i) Nevirapine syrup and
syringe for administration for HIV-positive women on prophylaxis
and treatment.

to the health facilities through the existing system. The
copackages were administered at the first ANC visit (≥14
weeks of gestation) and contained drugs through six weeks
postpartum, including Nevirapine (NVP) for HIV-exposed
infants. Pack 3 contained only one month of ART so women
on treatment for their own health still had to return monthly
to obtain refills. All packs contained ferrous sulphate, folic
acid, and Vitamin A and Vitamin B-complex, which were
not provided consistently and universally to pregnant women
prior to the pack’s implementation, and an instruction sheet.
All women were advised to bring the pack to each visit in
order to provide additional counseling and review of contents
and to assess adherence to both the PMTCT drugs and other
pack contents. The copackage differed from standard PMTCT
care primarily in the drug delivery mechanism: dispensing
a supply of maternal and infant drugs at the first ANC visit
to last through six weeks postpartum, particularly to target
HIV-positive women on prophylaxis in case they did not
return for a subsequent ANC visit or deliver in a health
facility. However, women were counseled on the importance
of returning to the facility for HIV and pregnancy-related
care. Women and their infants continued clinic follow-up
after six weeks postpartum with collection of additional
infant NVP for women on prophylaxis and additional ARV
for women on ART. The pack was first piloted in three
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districts in January 2011 and then rolled out nationally to the
remaining seven districts by August 2011.
In April 2013, the country shifted to universal, lifelong
ART for all HIV-positive pregnant and breastfeeding women
(known as “Option B+”), aligned with the 2013 WHO
PMTCT guidelines [16, 17]. The national program continued
with the use of Pack 1 and Pack 3. Therefore, it was important
to assess how women felt about this novel drug delivery
system (acceptability), how the copackage-related services
were delivered to women (feasibility), and how future use
could be aligned with the simplification of drug supply and
distribution systems and the ARV regimens and messaging
to women afforded by the Option B+ approach.

2. Materials and Methods
This was a mixed method, cross-sectional study. Structured
exit interviews (SI) and in-depth semistructured interviews
(SSI) with pregnant and early postpartum women were
conducted from December 2012 to May 2013.
2.1. Study Population and Recruitment. The study was conducted in six purposively selected districts out of the ten
districts in Lesotho. Three districts were those selected by the
MOH to first implement the mother/baby copackage. Three
comparable districts with later initiation were selected to
match the three geographical settings of Lesotho (Lowlands,
Foothills, and Highlands) represented in the initial implementing districts. Within each district, health facilities (HF)
were randomly selected as study sites using the probability
proportional-to-size (PPS) method to ensure all HF had the
same probability of being selected. SI were conducted in all
31 study sites while SSI were conducted in two study sites per
district (highest volume hospital and health center) for a total
of 12 sites.
HIV-positive and HIV-negative women who were attending a subsequent ANC visit and 6-week and 14-week postnatal
care (PNC) visits at study sites were eligible for participation
in interviews. Health care workers (HCW) introduced the
study and assisted in linking potential participants with study
staff. Study staff attempted to conduct SSI with HIV-positive
women who did not return to ANC or early PNC to capture
their experiences with the copackage and any influences it
may have had on their health-seeking behavior. We used the
routine PMTCT program follow-up system to identify and
trace women who had missed visits. When these women were
found, the community or health worker introduced them to
the study and invited them to speak with study staff at a
convenient time and location.
2.2. Structured Interview Methods. A sample of 196 women
in each of the three groups (HIV-negative, HIV-positive on
prophylaxis, and HIV-positive on ART) was targeted. We
estimated 85% of women would find the intervention both
acceptable and feasible, based on the MPP evaluation [15].
Assuming an expected proportion of 0.85, the large sample
normal approximation was used to calculate a two-sided 95%
confidence interval around the observed proportion with a
margin of error of 0.05 to determine a needed sample size for
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SI of 196. The target sample per HF was determined using PPS
based on routinely collected antenatal attendance program
data.
Women were selected through a random process by
which they were consecutively referred and screened on
days when study staff were present, until either the sample
size at each HF was reached or the data collection period
ended. HF targets were further divided into six subgroups of
roughly equal numbers based on all possible combinations
of visit type (ANC, PNC) and type of copackage received
(Pack 1, Pack 2, and Pack 3). Once a subgroup target was
reached, women in that particular group were no longer
eligible. Trained maternal and child health (MCH) study
nurses explained the study, obtained and documented verbal
informed consent, and conducted SI using data collection
instruments specifically designed according to the type of
visit and type of copackage received. All interviews were
conducted in Sesotho. SI involved closed-ended questions,
including a series of seven copackage acceptability (e.g., size,
convenience, and design) and eight copackage feasibility
(e.g., counseling, understanding, and clinic flow) statements.
Women were asked to indicate whether they agreed or
disagreed or had no opinion for each statement. They were
also asked to describe what they liked/disliked about the
copackage and their positive/negative experiences related to
its use. Interviewers selected precoded responses that best fit
the women’s answers and documented other responses that
could not be classified.
2.3. Semistructured Interview Methods. SSI guides covered
similar topics, but their open-ended nature allowed interviewers to probe more deeply. These interviews were intended
to capture richer and more complex information than the
SI. As such, a smaller approximate sample size range was
estimated in order to reach saturation of theme: 9–15 HIVpositive women (with approximately equal targets for women
on prophylaxis and ART) and 4–6 HIV-negative women
per HF for a total of 108–180 and 48–72, respectively, with
subgroup targets by visit type (ANC, 6-week PNC, 14-week
PNC). SSI study staff were different from those conducting
SI and were trained in qualitative research methods. Consecutive recruitment of women on days when study staff
were present was similar to the SI process. If SI and SSI
recruitment were taking place at the same HF on the same
day, women were first approached to participate in the SSI;
if they declined, they were asked whether they were willing
to participate in the shorter SI. SSI were audio recorded and
were simultaneously transcribed and translated into English.
Transcripts were reviewed by the study coordinators and/or
investigators once translated.
2.4. Data Analysis. Data from close-ended questions in SI
and SSI were entered into a Microsoft Access database (2007)
using a double data entry and verification system. Descriptive
statistics were calculated and reported for key characteristics
of the study participants and agreement with acceptability
and feasibility statements and reported experiences. Means
and standard deviations were reported for all continuous
variables (Table 1) and frequencies and percentages were

4

AIDS Research and Treatment
Table 1: Characteristics of study participants.

Total 𝑁 (%)
Continuous variable
Age
Gravida
Categorical variable
Districts
Qacha’s Nek
Mafeteng
Butha Buthe
Berea
Mohale’s Hoek
Mokhotlong
Status/regimen
HIV-negative
HIV-positive/prophylaxis
HIV-positive/ART
HIV-positive/unknown regimen∗
Visit
ANC
PNC
ANC visit pack received
1st
2nd
3rd
≥4th
Did not receive pack
Unknown∗
Number of ANC visits (PNC only)
1
2
3
4
>4
Unknown∗
Did not attend ANC∗
∗

Structured interview (SI) participants
523
𝑁
Mean (SD)
522
26.6 (6.3)
520
2.1 (1.3)
𝑁 (%)

Semistructured interview (SSI) participants
204
𝑁
Mean (SD)
201
26.5 (6.0)
203
2.3 (1.4)
𝑁 (%)

Total
727
𝑁
Mean (SD)
723
26.6 (6.2)
723
2.2 (1.3)
𝑁 (%)

26 (5.0)
125 (23.9)
51 (9.8)
173 (33.1)
86 (16.4)
62 (11.9)

36 (17.7)
43 (21.0)
31 (15.2)
35 (17.2)
35 (17.2)
24 (11.8)

62 (8.5)
168 (23.1)
82 (11.3)
208 (28.6)
121 (16.6)
86 (11.8)

223 (43.1)
152 (29.4)
142 (27.5)
6

67 (33.7)
72 (36.2)
60 (30.2)
5

290 (40.5)
224 (31.3)
202 (28.2)
11

262 (50.1)
261 (49.9)

86 (42.2)
118 (57.8)

348 (47.9)
379 (52.1)

456 (87.7)
48 (9.2)
7 (1.3)
1 (0.2)
8 (1.5)
3

174 (85.3)
20 (9.8)
2 (1.0)
0 (0)
8 (3.9)
0

630 (87.0)
68 (9.4)
9 (1.2)
1 (0.1)
16 (2.2)
3

9 (3.8)
32 (13.4)
61 (25.5)
69 (28.9)
68 (28.5)
19
3

5 (4.6)
13 (11.9)
32 (29.4)
28 (25.7)
31 (28.4)
9
0

14 (4.0)
45 (12.9)
93 (26.7)
97 (27.9)
99 (28.4)
28
3

Excluded from the percentage calculation.

reported for all categorical variables (Tables 1 and 2 and
Figures 2 and 3). Differences in (1) the level of agreement
with acceptability and feasibility statements and (2) the
experience of either positive or negative consequences as a
result of pack receipt among HIV-negative women, HIVpositive women on prophylaxis, and HIV-positive women on
ART were examined with generalized estimating equations
(GEE) using the binomial distribution with the logit link
for dichotomous outcomes or the multinomial distribution
with the cumulative logit link for ordinal outcomes. Select
significant findings are highlighted in the text. Compound

symmetry and independent working correlation structures
were considered to account for the clustering of women
in multiple facilities. Score tests were used to test the proportional odds assumption, and the Tukey-Kramer method
for 𝑃 value adjustment was used to account for multiple
comparisons. All statistical tests were two-sided and the
level of statistical significance was set at 0.05. All data were
analyzed in Washington, DC, USA, using SAS/STAT software
version 9.3 (Cary, North Carolina).
SSI transcripts were imported into MAXqda (V10). A
codebook was created based on the research objectives and
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Table 2: Women’s positive and negative experiences with the pack reported in structured interviews.
HIVpositive/prophylaxis
(𝑛 = 148)
What positive experiences have you had with the pack?
Pack motivated to disclose to spouse
41 (18.7)
32 (21.6)
Pack motivated to disclose to family
14 (6.4)
22 (14.9)
Received support from partner after disclosure
47 (21.5)
40 (27.0)
Received support from family member after disclosure
8 (3.7)
26 (17.6)
Led to unplanned disclosure with acceptance from partner
5 (2.3)
6 (4.1)
Community treated me better with pack
13 (5.9)
9 (6.1)
Motivated me attend clinic to have healthy baby
31 (14.2)
30 (20.3)
Allowed me to attend clinic less often
21 (9.6)
10 (6.8)
Helped take all the pills as instructed
83 (37.9)
54 (36.5)
Identified me as pregnant
30 (13.7)
4 (2.7)
Drug contents improved mother/child health
17 (7.8)
6 (4.1)
No positive experiences
30 (13.7)
28 (18.9)
HIVHIV-negative
𝑁 (%)
positive/prophylaxis
(𝑛 = 218)
(𝑛 = 149)
What negative experiences have you had with the pack?
Partner found out status and was verbally abused
0
1 (0.7)
Partner found out status and was treated badly
0
1 (0.7)
Partner found out status and was abandoned
0
1 (0.7)
Family member found out status and was treated badly
0
2 (1.3)
Confused about pack and drugs
0
1 (0.7)
Difficult because I had to hide pack
1 (0.5)
3 (2.0)
Having drugs in pack made me forget to take drugs
1 (0.5)
1 (0.7)
People treated me badly when they saw pack
2 (0.9)
3 (2.0)
Others suspected/discovered HIV+ status
1 (0.5)
1 (0.7)
Identified me as pregnant
40 (18.3)
25 (16.8)
No negative experiences
171 (78.4)
112 (75.2)
𝑁 (%)

HIV-negative
(𝑛 = 219)

variables of interest. Data were coded by a team in the US
and Lesotho and reviewed for consistency by one investigator.
Textual data were carefully reviewed to identify recurrent
patterns and themes and draw conclusions connected to the
study questions. Data were summarized through descriptive,
text-based summaries and data display matrices. Both deductive codes based on research questions and inductive codes
derived from the data were utilized.
2.5. Ethical Approval. This study was approved by the George
Washington University Institutional Review Board (IRB), the
Baylor College of Medicine Lesotho IRB, and the Lesotho
MOH ethical review committee. All participants underwent
a verbal informed consent process in Sesotho using an IRBapproved verbal consent text with documentation of consent
by study staff.

3. Results
3.1. Study Population. 523 women participated in SI and 204
women participated in SSI (Table 1). Overall, 348 women

HIV-positive/ART
(𝑛 = 142)

Total
(𝑛 = 509)

22 (15.5)
9 (6.3)
34 (23.9)
15 (10.6)
3 (2.1)
13 (9.2)
34 (23.9)
6 (4.2)
41 (28.9)
11 (7.8)
5 (3.5)
32 (22.5)

95 (18.7)
45 (8.8)
121 (23.8)
49 (9.6)
14 (2.8)
35 (6.9)
95 (18.7)
37 (7.3)
178 (35.0)
45 (8.8)
28 (5.5)
90 (17.7)

HIV-positive/ART
(𝑛 = 142)

Total
(𝑛 = 509)

0
0
0
3 (2.1)
1 (0.7)
2 (1.4)
0
3 (2.1)
4 (2.8)
18 (12.7)
113 (79.6)

1 (0.2)
1 (0.2)
1 (0.2)
5 (1.0)
2 (0.4)
6 (1.2)
2 (0.4)
8 (1.6)
6 (1.2)
83 (16.3)
396 (77.8)

were interviewed in ANC and 379 in PNC. 290 were HIVnegative and 437 were HIV-positive (𝑛 = 224 on prophylaxis,
𝑛 = 202 on ART, 𝑛 = 11 with unknown regimen) with a
mean age of 26.6 years. Women with unknown regimen did
not receive a pack; they were asked close-ended demographic
and pregnancy-related questions only since they could not
address questions on copackage acceptability and feasibility.
The majority of women (87.0%) received the pack at their
first ANC visit; 16 women (2.2%) did not receive the pack.
Among pregnant women who participated in SI and SSI
in ANC, 91.3%, 94.4%, and 87.5% of HIV-negative, HIVpositive women on prophylaxis, and HIV-positive on ART,
respectively, brought the pack with them to the ANC visit
when the interview was conducted.
Attempts were made to locate 79 women who were
identified as clinic defaulters. 45 women were found; of whom
16 were still in care and were misclassified as defaulters. Of
the other 29, eight were deemed ineligible by study staff,
two declined to be interviewed, and 14 did not arrive for
their interview appointments (information was missing for
one woman). Of the four who arrived for their interview
appointments, study staff failed to conduct the interview
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Design of pack has helped you
better understand how to take
your medicine
Overall you find pack a good
way of receiving pills you need

The health worker demonstrated how
to use all contents in the pack when
you first received it
On the day you started taking pills from
pack, you understood how to take them

It is convenient to have the
pills you need in one pack

As of today, you understand how to
take the pills/contents from pack
correctly
Time spent on counseling about
use of pack when you first
received it was enough

Pack is easy to carry

All your questions about pack were
answered when you first received it

Pack is easy to store

Time spent on pack counseling at
this/subsequent visit(s) was enough

Instruction sheet
in pack was clear

All your questions about pack were
answered at this/subsequent visit(s)

Size of pack is too big
0 10 20 30 40 50 60 70 80 90 100
(%)
HIV-positive on ART (n = 142)
HIV-positive on prophylaxis (n = 151)
HIV-negative (n = 219)
N = 512
(1–3 missing from some variables)

Figure 2: Percentage of structured interview participants that agree
with the copackage acceptability statements by HIV status group.
(Possible responses to statements included agree, disagree, and no
opinion. “No opinion” responses ranged from 0.4 to 2.0% of the
three groups combined for each statement, except the instruction
sheet statement, in which 13.7%, 24.8%, and 22.0% of HIV-negative,
HIV-positive on prophylaxis, and HIV-positive on ART women
responded with “no opinion,” because they did not have or did not
use the sheet.)

for one woman, one woman was determined ineligible after
interviewing, and two interviews were conducted. Among the
other 34 women, 23 could not be found, nine had relocated,
and two were deceased.
3.2. SI Acceptability. Nearly all (96.3%) SI participants found
the copackage to be acceptable (Figure 2). There were high
levels of agreement across all three groups (HIV-negative,
HIV-positive on prophylaxis, and HIV-positive on ART) with
the acceptability statements. Half (50.7%) of participants felt
the size of the pack was too big. Significantly more women
on ART (89.4%) felt the pack was easy to carry than HIVnegative women (79.9%, OR = 0.47, 95% CI: 0.30, 0.74, 𝑃 <
0.0003). (The intraclass correlation coefficients (ICCs) for
acceptability and feasibility statement comparisons across
groups were all negligible (<0.01).) The instruction sheet,
meant to be included in each pack to provide supplemental
guidance on use, was not used or missing from the pack in
13.7%, 24.8%, and 22.0% of reports by HIV-negative, HIVpositive on prophylaxis, and HIV-positive on ART women,
respectively. A missing or unused instruction sheet was
reported by significantly more women on prophylaxis compared to HIV-negative women (OR = 2.43, 95% CI: 1.33, 4.45,
𝑃 < 0.0017). Supplemental Table 1, in Supplementary Material available online at http://dx.doi.org/10.1155/2015/435868,

Using pack to give your drugs does not
cause you to stay in clinic too long

0 10 20 30 40 50 60 70 80 90 100
(%)
HIV-positive on ART (n = 142)
HIV-positive on prophylaxis (n = 152)
HIV-negative (n = 219)
N = 513 (1 missing from 1 variable)

Figure 3: Percentage of structured interview participants that agree
with the copackage feasibility statements by HIV status group.
(Possible responses to statements included agree, disagree, and
no opinion. For most statements, “no opinion” responses ranged
from 0.6 to 7.0% of the three groups combined for each statement.
The exceptions were “all questions about the pack were answered”
in which 12.8%, 10.5%, and 8.5% of HIV-negative, HIV-positive
on prophylaxis, and HIV-positive on ART women, respectively,
responded with “no opinion,” at first visit and 16.1%, 13.2%, and
12.7%, respectively, responded with “no opinion,” at this visit (if
interviewed in ANC) or subsequent visits (if interviewed in PNC)
because they did not have questions.)

provides the GEE results (𝑃 values, ORs and 95% CIs) for each
acceptability statement by HIV status group.
3.3. SSI Acceptability. Women participating in SSI also found
the copackage acceptable but agreed the packs were too
big and often referred to it as luggage. They recommended
reducing the pack’s size so that it could fit in a handbag. In
order for packs to appear identical, all packs contain the same
inner boxes, though some were empty for HIV-negative and
HIV-positive women on ART, but this feature made the packs
seem unnecessarily large to some women:
The pack should be smaller. . . again another
reason it is because some of my boxes were empty
so I was saying that I do not see a point of being
given such a big empty box. (HIV-positive woman
on ART in PNC)
Women made recommendations to improve pack design
and its transport, including adding a strap so that it can be
carried as a handbag. Labeling the diagrams on the pack
flap in Sesotho (not English); ensuring the instruction sheet
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is included in pack and placed prominently inside; and
writing the dosage on pill bags and bottles and ordering
them by month so women would understand to finish one
before opening the next one were other recommendations to
improve the pack.
3.4. SI Positive and Negative Experiences. While 17.7% of
women reported no positive experiences using the pack, the
majority (77.8%) reported no negative experiences (Table 2).
The most-frequently mentioned positive experience by 35.0%
of women was that the pack helped them to take their pills
as instructed. In total, only 7.3% of women indicated that
the pack allowed them to attend clinic less often. The most
common negative experience reported by 16.3% of women
was that the pack identified women as pregnant before
they were ready to disclose. In contrast, 8.8% of women
considered being identified as pregnant by the pack a positive
experience. HIV-negative women were more likely to report
identification of pregnancy as a positive experience (13.7%)
than HIV-positive women on prophylaxis (2.7%, OR = 5.30,
95% CI: 1.91, 14.72, 𝑃 < 0.0004). Three instances of illtreatment by partners who discovered women’s HIV-positive
status because of the pack were reported. In GEE models,
there were no statistically significant differences in those who
reported any positive pack-related experience (87.4%, 82.7%,
and 79.4%, 𝑃 = 0.17) or any negative experience (22.0%,
25.5%, and 21.6%, 𝑃 = 0.65) among the HIV-negative, HIVpositive on prophylaxis, and HIV-positive on ART groups,
respectively.
3.5. SSI Positive and Negative Experiences. Receipt of all pills
at once and the health-promoting qualities of the pack and
contents were the aspects women most liked about the pack.
The most commonly cited positive experiences were that the
pack or drug contents promoted healthy pregnancies and
deliveries; partners or family members accepted and supported women using pack; and women felt happy or excited
when walking to/from the clinic with the pack. One woman
describes going home with the pack after she first received it:
It was good. It’s because I think this pack and pills
will help my baby to be born healthy. I was happy.
(HIV-positive woman on prophylaxis in ANC)
The fact that all packs have identical outer packaging
helped some women regardless of status to feel comfortable
carrying the pack and deflect any attention or questions
about their pack, simply by responding that all pregnant
women received them. While a few women reported rumors
in the community that the pack was associated with HIV,
particularly during early months of implementation, most
people came to realize that the copackage was provided to all
women seeking antenatal services.
I like the pack because all people are given the
same bag and no one will see if you are given
HIV drugs. It enables one’s status to be known
to that person alone. (HIV-positive women on
prophylaxis in PNC)
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Similar to SI, pregnancy identification was one of the
most frequently mentioned dislikes, as well as heeding the
advice of nurses to carry the pack with them everywhere.
There were reports from both HIV-negative and HIV-positive
women that they hid the pack in another bag when in public.
I do not like carrying the pack, I put it in my bag
because I do not want people to see that I am
pregnant and know that whenever I am carrying
the pack, I am going to the clinic even though my
pregnancy is not visible. (HIV-negative woman in
PNC)
Overall, the frequency of negative experiences reported
because of the pack was low. These included feelings of
discomfort or shame when carrying the pack in the community; inadvertent disclosure of HIV status when community
members incorrectly perceived that all women with the pack
were HIV-positive; and being mocked by community members when carrying the pack. There were also few problems
reported with women’s partners or mothers-in-law as a result
of receiving the pack. While not related to the pack itself,
some women did not like the supplements in the packs as they
felt taking them would result in large infants that would make
delivery more difficult. Negative experiences were reported
by one of the two women who missed visits. The woman felt
stigmatized by a neighbor who assumed she was HIV-positive
after being seen with the pack. She also reported initial confusion due to all of the information provided during initial
copackage counseling. However, neither woman reported
receipt of the copackage as the reason for missing visits.
3.6. SI Feasibility. There were high levels of agreement with
feasibility statements among all three groups and any differences were statistically nonsignificant (Figure 3). 95.1%
of women understood how to take pills from the pack
from the first day it was used and 93.4% understood on
the day of the interview. Time spent on counseling at visit
when pack was first received as well as at subsequent visits
was considered adequate by 85.2% and 84.8% of women,
respectively. Approximately 38% felt use of the pack caused
clinic delays. Supplemental Table 2 provides the GEE results
(𝑃 values, ORs and 95% CIs) for each feasibility statement by
HIV status group.
3.7. SSI Feasibility. Most women said that it was easy for them
to take medication from the pack. Reported drug-taking
errors were rare (e.g., continuing AZT prophylaxis after delivery, taking the wrong supplement dosage). SSI participants
described longer counseling sessions when the pack was first
dispensed, but that counseling was helpful and the length
was appropriate to the topics being discussed. They also generally felt their questions were adequately addressed during
counseling. Women were counseled that the purpose of the
pack was to promote mother and child health and prevent
MTCT, though there was some difficulty in understanding
the purpose of the empty boxes and carrying it to each visit,
particularly for HIV-negative women. For instance, some
HIV-negative and HIV-positive on ART women had not been
counseled to understand that they had an empty delivery
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box and why (this medication was only included in the HIV
prophylaxis pack). During counseling, some women reported
that nurses referred to the information sheet without explaining it and were told to read it on their own or it was not mentioned at all. Those that used the sheet found it helpful. Few
women reported little or no counseling at follow-up visits.
Most SSI participants who had attended ANC for previous pregnancies agreed waiting times increased following
the introduction of the copackage, though quality of services
had improved due to more education and counseling and
adherence assessments. When asked if services have changed
with pack introduction, one woman responded:
They have changed a lot because this time we
have been given such help. . .I realized that we get
services in a good way. You are examined, whether
you like it or not you have to be examined for the
sake of your baby. . .back then when they see you
complaining they left you without examining youthey did the other small things and left you- but
now we are cared for. (HIV-positive woman on
ART in PNC)
Women perceived the counseling and time spent at the
clinic to be longer than previously experienced. However,
most women appreciated the time at clinic because they
felt they were receiving more comprehensive services: they
received pills that they had not received previously and they
were counseled on the entire course of pregnancy and beyond
and on the importance of the drugs contained in the pack.
Their pack contents were also physically checked instead of
simply asking women if they had taken their drugs.
The majority of women in SSI preferred to receive all
of their pregnancy and early postpartum medications in the
pack at one time, largely because they felt it would be difficult
to return to clinic by the exact day that their pills finished (e.g.,
due to travel, lack of transport, or transport money). However, one respondent described the reason for her preference
was that it helped understand the importance of the medicine:
I want it to be given once. . .If we are given it packet
after packet – we will not get the benefit of the pack
like the picture so that we are able to learn about
them, and the instruction sheet and the boxes in
here. We cannot be able to know about it, I think
when I take that one packet and go home with it
I will not know anything about the benefits of this
pack. (HIV+ woman on ART in ANC)

4. Discussion
Overall, women felt that the copackage was an acceptable
and feasible way of receiving HIV-related and safe motherhood medicines during pregnancy and early postpartum in
Lesotho. Women expressed high levels of agreement with
statements related to overall pack acceptability as well as
the ease to which the pack was stored, carried, and used to
take medicine. Women also agreed with statements regarding
sufficient counseling and understanding of the pack and its
contents. There were few negative experiences associated with

pack and most women expressed a preference to receive
prepackaged medicines. Despite overall acceptance, there
were suggestions noted for improvement to pack design,
largely related to the pack’s size, to draw less attention to
women carrying the pack and to improve ease of its transport.
Other evaluations of prepackaged medicines had similarly favorable findings. There were high levels of acceptability
and utilization of contents among mothers in Pakistan provided with a prepackaged intervention, including oral rehydration salts and Zinc tablets distributed for home use and
aimed at diarrhea treatment for their young children [18]. A
“mama kit” implemented in Uganda containing preventative
malaria treatment was also accepted by the pregnant women
to whom it was administered [19].
The pack inadvertently disclosed women’s pregnancies
earlier than some would have liked, irrespective of HIV status, though women did not indicate that this prevented them
from attending clinic. In contrast, Andrew et al. found that
some women, particularly those stigmatized for being pregnant, such as adolescents or single women, were discouraged
from attending ANC, since they felt that doing so would
disclose their pregnancies to the community [20].
The improvement in quality of services many women
attributed to the pack may have been because the pack was
accompanied by a change in counseling that focused more
individual attention on women and the importance of “soft”
skills in counseling in addition to the messaging. Ugandan
“mama kits” were accompanied by midwife training that
included customer care and how to provide a friendly environment. Mbonye et al. found that among the significant
factors influencing adherence to treatment was promise of
the pack and kind midwives, highlighting the importance of
friendly services that help women feel cared for and valued
[19]. Authors concluded that a patient-centered approach
over authoritarian or paternalistic approaches to counsel
pregnant women to stop smoking in South Africa was
preferred as it helped to facilitate better relationships between
midwives and patients [21]. Positive feedback from nurses,
among other factors, aided in effective communication with
patients during family planning consultations in Indonesia
[22].
Few women reported attending clinic less often due to
the copackaged medicines dispensed at the first ANC visit.
Therefore the pack does not appear to be a barrier to the
WHO recommendation of attending at least four ANC visits,
based on this limited finding. However, differences in the
delivery and uptake of services using the pack compared with
provision of the Option A regimen without the pack were
investigated retrospectively using routinely collected data and
will be presented elsewhere. It is not possible to discern
from these results the extent to which the pack addressed
the issue of providing sustained medication to the group
of women who only attended one ANC visit. In addition,
women who did not return to ANC after pack receipt may
not have found the pack as acceptable and feasible compared
to women regularly attending care. While efforts were made
to gather experiences from women who did not return for
subsequent visits, there was limited representation from this
group. Given that the copackage was rolled out nationwide in
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Lesotho by the time of the evaluation, it was not possible to
have a comparison group of women who did not receive the
pack. However, multigravida women in SSI provided valuable
responses in their comparisons of pregnancy-related experiences at the clinic preceding and following pack introduction.
Another study limitation is that there may be a social
desirability bias skewing women’s responses in a positive
direction. Women who responded with “no opinion” to any
of the acceptability and feasibility statements (e.g., for women
who did not have questions to be answered during counseling) were included in the denominator, but not the numerator, for the percentage calculation of women who agreed with
these statements. Therefore, the percentages are conservative
estimates for most positive statements and would be higher if
these responses were removed from the denominator.
While it was not part of this evaluation, an assessment
of the costs would be an important undertaking for national
program planners to make a decision about long-term implementation of the pack. Providing the copackage to all women
is more costly than targeting HIV-positive women. However,
these findings indicate that having identical packs dispensed
to all women did contribute to women’s acceptability of
the pack and that the benefits of the pack extend beyond
those with an HIV-positive diagnosis. In addition, the initial
copackaging was designed and produced externally, which
is considerably more costly than having the revised packs
designed, produced, and filled locally. Reducing the size
of the pack and eliminating the inner boxes which are no
longer necessary under the Option B+ program would help to
minimize pack costs. The pack size was based on the group of
women requiring the greatest number of contents, pregnant
women on ARV prophylaxis, which is no longer relevant
under the current PMTCT approach. The simplification of
treatment regimens under Option B+ is aligned with a
primary purpose of the pack, to simplify drug distribution
and delivery systems. Moreover, Option B+ implementation
could be enhanced by the prepackaging and counseling
aspects of the pack.

5. Conclusions
This study found that an innovative prepackaged drug
delivery mechanism is a feasible and acceptable alternative
to traditional ANC and PMTCT drug dispensing. Women
generally liked the pack, which may be attributed in large part
to more comprehensive counseling and perceived improvement in quality of care that accompanied its use. Suggested
improvements to the size and design of packs incorporated
with modifications needed to reflect the current Option B+
regimen should further increase both the acceptability and
feasibility of this mechanism. Results from this evaluation
have significant implications for the PMTCT program in
Lesotho, as well as globally, as other countries consider implementation of similar copackaging mechanisms for integrated
drug distribution to maximize the health of women and
children.
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